Anavex Life Sciences Corp.
OPTIMIZED SIGMA-1 AGONIST METHOD OF RESPONDER SELECTION AND TREATMENT

Abstract:

The present disclosure provides genetic polymorphisms associated with an altered response of a subject to Sigma-1 receptor therapy. Also described is use of the polymorphisms to personalize treatment for subjects in need of Sigma-1 receptor therapy such as treatment of neurodevelopmental and neurodegenerative diseases and conditions.